Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14

Overview

cited authors

Pratley, Richard E.; Husain, Mansoor; Lingvay, Ildiko; Pieber, Thomas R.; Mark, Thomas; Saevereid, Hans A.; Moller, Daniel Vega; Zinman, Bernard; DEVOTE Study Grp

authors

Pratley, Richard Edwin, MD

Publication Date

November 15, 2019

webpage

Web of Science

published in

CARDIOVASCULAR DIABETOLOGY Journal

Research

keywords

Clinical trial
Hospitalization for heart failure
Insulin degludec
Severe hypoglycemia
Type 2 diabetes

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.